DCT

2:26-cv-10991

PH Health Ltd v. Steriscience Pte Ltd

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: PH Health Ltd. v. Steriscience Pte. Ltd., 2:26-cv-10991, D.N.J., 08/26/2026
  • Venue Allegations: Venue is asserted on the basis that the Defendant is a foreign company not residing in any U.S. judicial district and may therefore be sued in any district.
  • Core Dispute: Plaintiffs allege that Defendant's proposed generic epinephrine pre-filled syringe product, for which it seeks FDA approval via an Abbreviated New Drug Application (ANDA), will infringe four U.S. patents directed to stable epinephrine formulations.
  • Technical Context: The technology concerns pharmaceutical compositions of epinephrine engineered to have improved stability and a longer shelf-life by minimizing the formation of degradants.
  • Key Procedural History: This action was initiated under the Hatch-Waxman Act following Plaintiffs' receipt of a notice letter, dated July 16, 2026, in which Defendant stated it had filed ANDA No. 218918 with a Paragraph IV Certification. This certification alleges that three of the four patents-in-suit are invalid, unenforceable, or will not be infringed. The complaint notes that the patents-in-suit were the subject of several prior, now-closed lawsuits in various districts, though the current Defendant was not a party to those actions.

Case Timeline

Date Event
2015-03-13 Earliest Priority Date for '876, '657, '024, '938 Patents
2015-09-01 U.S. Patent No. 9,119,876 Issues
2016-03-29 U.S. Patent No. 9,295,657 Issues
2022-05-24 U.S. Patent No. 11,337,938 Issues
2025-04-22 U.S. Patent No. 12,280,024 Issues
2026-07-16 Defendant's Notice Letter Sent to Plaintiffs
2026-08-26 Complaint Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 9,119,876 - Epinephrine formulations

Issued September 1, 2015

The Invention Explained

  • Problem Addressed: The patent's background section describes that existing epinephrine formulations, such as Adrenalin®, have a limited shelf life due to chemical degradation. The primary degradants are identified as epinephrine sulfonic acid (ESA) and D-epinephrine, an enantiomer of the active ingredient L-epinephrine that has insignificant therapeutic activity '876 Patent, col. 1:53-62
  • The Patented Solution: The invention claims to provide a more stable epinephrine composition that resists degradation. The specification explains that a key mechanism for instability is the racemization of L-epinephrine to D-epinephrine, which is slowed at a higher pH. However, the antioxidant commonly used (sodium metabisulfite) degrades and lowers the pH over time. The patented solution introduces a "pH raising agent," which acts as a buffer to counteract this pH drop, thereby maintaining a more stable environment for the epinephrine and extending the product's shelf life '876 Patent, col. 4:1-15 '876 Patent, col. 7:42-53
  • Technical Importance: Developing a room-temperature stable, ready-to-use injectable epinephrine formulation with an extended shelf life reduces waste and ensures the reliability of a critical emergency-use drug '876 Patent, col. 1:20-29

Key Claims at a Glance

  • The complaint alleges infringement of one or more claims of the '876 patent Compl. ¶31 Independent claim 1 is representative of the composition claims.
  • Claim 1 of the '876 Patent requires:
    • A composition comprising epinephrine and/or its salts within a specific concentration range (0.5 to 1.5 mg/mL).
    • A tonicity regulating agent (6 to 8 mg/mL).
    • A pH raising agent (2.8 to 3.8 mg/mL).
    • An antioxidant (0.1 to 1.1 mg/mL) that is sodium bisulfite and/or sodium metabisulfite.
    • A pH lowering agent (0.001 to 0.010 mL/mL).
    • A transition metal complexing agent (0.01 to 0.4 mg/mL).

U.S. Patent No. 9,295,657 - Epinephrine formulations

Issued March 29, 2016

The Invention Explained

  • Problem Addressed: The patent addresses the same problem as its parent '876 patent: the limited shelf life of epinephrine solutions due to the formation of degradants like ESA and D-epinephrine '657 Patent, col. 1:53-62
  • The Patented Solution: The '657 patent claims a method of using the stable epinephrine formulation described in the '876 patent to treat specific medical conditions. The underlying technical solution is identical: using a buffered formulation with a pH raising agent and an antioxidant to maintain stability over time '657 Patent, col. 4:1-15 '657 Patent, col. 7:42-53
  • Technical Importance: This patent extends protection from the composition itself to the specific, approved methods of using that composition for emergency medical treatment, a key aspect for pharmaceutical patent enforcement.

Key Claims at a Glance

  • The complaint alleges infringement of one or more claims of the '657 patent Compl. ¶39 Independent claim 1 is a method-of-use claim.
  • Claim 1 of the '657 Patent requires:
    • A method of treating a condition by administering a composition.
    • The composition contains epinephrine, a tonicity regulating agent, a pH raising agent, an antioxidant (sodium bisulfite/metabisulfite), a pH lowering agent, and a transition metal complexing agent in the same concentration ranges as claim 1 of the '876 patent.
    • The treated condition is selected from a list including anaphylaxis, bronchospasm, cardiac arrhythmias, and others.

U.S. Patent No. 12,280,024 - Epinephrine formulations

Issued April 22, 2025

  • Technology Synopsis: This patent, part of the same family, is also directed at stable epinephrine formulations. It claims a composition defined not only by its ingredients but also by a specific impurity profile-about 3% or less total impurities-after six months of storage under defined conditions, providing a performance-based limitation '024 Patent, abstract '024 Patent, claim 1
  • Asserted Claims: The complaint asserts one or more claims of the '024 patent Compl. ¶47
  • Accused Features: The complaint alleges infringement by the Defendant's Proposed ANDA Product containing epinephrine Compl. ¶47

U.S. Patent No. 11,337,938 - Epinephrine formulations

Issued May 24, 2022

  • Technology Synopsis: This patent claims a pre-filled syringe containing a specific epinephrine composition. The claims recite precise concentrations for each component (e.g., 0.0457 mg/mL sodium metabisulfite) and require that the composition has no more than about 1.5% total impurities after two months of long-term storage, linking the formulation directly to a delivery device and a specific stability outcome '938 Patent, abstract '938 Patent, claim 1
  • Asserted Claims: The complaint asserts one or more claims of the '938 patent Compl. ¶56
  • Accused Features: The complaint alleges infringement by the Defendant's Proposed ANDA Product, which is a pre-filled syringe containing epinephrine (Compl. ¶¶1; Compl. ¶56).

III. The Accused Instrumentality

Product Identification

The accused instrumentality is Defendant's "Proposed ANDA Product," described as a generic version of Adrenalin® (epinephrine) in pre-filled syringes, for which Defendant seeks FDA approval under ANDA No. 218918 Compl. ¶1

Functionality and Market Context

The complaint alleges that the Proposed ANDA Product is bioequivalent to Plaintiffs' Adrenalin® product Compl. ¶26 Adrenalin® is indicated for the emergency treatment of severe allergic reactions, including anaphylaxis, and to increase blood pressure in adult patients with septic shock Compl. ¶21 The complaint does not provide specific details regarding the formulation of the Proposed ANDA Product itself, other than to state on information and belief that it contains epinephrine and that its proposed label will instruct healthcare providers on its use Compl. ¶27 Compl. ¶31

IV. Analysis of Infringement Allegations

The complaint does not provide sufficient detail to map specific features of the Proposed ANDA Product to the elements of the asserted claims. The infringement allegations are made "on information and belief" and assert that the presence and use of epinephrine in the Proposed ANDA Product will infringe the patents-in-suit Compl. ¶31 Compl. ¶39 Compl. ¶47 Compl. ¶56 The complaint contains no claim charts or specific factual allegations detailing the composition of the accused product.

The central theory of infringement appears to be that by seeking to market a generic epinephrine product for the same indications as Adrenalin®, the Defendant's product will necessarily practice the inventions claimed in the patents-in-suit, which are listed in the FDA's Orange Book for Adrenalin® Compl. ¶14 Compl. ¶16 Compl. ¶18

  • Identified Points of Contention:
    • Evidentiary Questions: A primary point of contention will be factual: does the exact formulation of the Defendant's Proposed ANDA Product, as disclosed in its confidential ANDA submission, fall within the specific concentration ranges for each of the components required by the independent claims of the patents-in-suit?
    • Scope Questions: The dispute may turn on whether the accused product meets the performance-based limitations present in the later patents, such as the total impurity levels after a specified storage period (e.g., '938 Patent, claim 1; '024 Patent, claim 1). Proving infringement would require evidence from stability studies of the Defendant's product.
    • Method of Use Infringement ('657 Patent): For the method claims, a key question will be whether the proposed label for the Defendant's product will instruct medical professionals to administer the drug for one of the specific conditions recited in the claims, thereby inducing infringement Compl. ¶41

No probative visual evidence provided in complaint.

V. Key Claim Terms for Construction

  • The Term: "pH raising agent"

    • Context and Importance: This term is central to the core inventive concept of all asserted patents, which is to improve stability by controlling the formulation's pH. The scope of this term will be critical in determining whether the defendant's formulation, which likely contains some form of pH adjuster, infringes.
    • Intrinsic Evidence for Interpretation:
      • Evidence for a Broader Interpretation: The specification provides a long list of potential "pH raising agents," including various hydroxides and salts of lactate, tartarate, glutamate, and acetate, which could suggest the term covers any substance that serves to raise pH '876 Patent, col. 5:35-43
      • Evidence for a Narrower Interpretation: The specification repeatedly describes the function of the "pH raising agent" as part of a "buffer system" that provides "resistance to significant change in pH" '876 Patent, col. 4:9-15 This functional language may support a narrower construction requiring not just any base, but a compound or system that provides a specific buffering capacity within a relevant pH range.

  • The Term: "antioxidant"

    • Context and Importance: The interaction between the antioxidant and the pH raising agent is a key aspect of the patented technology. While the claims of the lead patents specify "sodium bisulfite and/or sodium metabisulfite," the interpretation of the antioxidant's role and its required concentration could still be a point of dispute.
    • Intrinsic Evidence for Interpretation:
      • Evidence for a Broader Interpretation: The specification provides a lengthy list of potential antioxidants beyond sulfites, such as ascorbic acid and glutathione '876 Patent, col. 7:26-51 While not recited in the independent claims of the lead patents, this could be relevant for arguments related to the doctrine of equivalents.
      • Evidence for a Narrower Interpretation: The claims themselves limit the term to "sodium bisulfite and/or sodium metabisulfite." Furthermore, the specification extensively discusses the specific problem of sulfite degradation leading to a pH drop, a problem the "pH raising agent" is designed to solve '876 Patent, col. 4:1-15 This context suggests the term should be understood in its specific chemical environment, where its degradation products directly impact the stability mechanism at the heart of the invention.

VI. Other Allegations

  • Indirect Infringement: The complaint alleges induced infringement on the basis that Defendant, upon approval, will "instruct healthcare providers to use the Proposed ANDA Product in accordance with the proposed product labeling" Compl. ¶33 Compl. ¶41 Compl. ¶49 Compl. ¶58
  • Willful Infringement: Willfulness is not explicitly pleaded as a separate count, but the factual predicates are alleged. The complaint asserts that Defendant had knowledge of the patents when it submitted its ANDA, based on its filing of a Paragraph IV Certification against them Compl. ¶35 Compl. ¶43 Compl. ¶51 Compl. ¶60 This alleges pre-suit knowledge of the patents and the alleged infringement.

VII. Analyst's Conclusion: Key Questions for the Case

  1. A central evidentiary question will be one of compositional identity: does the formulation of Defendant's Proposed ANDA Product, which remains confidential, contain the specific ingredients within the precise concentration ranges recited in the asserted patent claims? The case will depend heavily on discovery into the contents of ANDA No. 218918.

  2. A key legal question will be one of claim scope: how will the court construe the term "pH raising agent"? A narrow construction requiring a functional "buffer system" might provide Defendant with a non-infringement defense if its product uses a simple base for one-time pH adjustment, whereas a broader construction covering any pH-adjusting substance would favor the Plaintiffs.

  3. A significant issue for the later-issued patents will be performance-based infringement: can Plaintiffs prove that Defendant's product will meet the claimed impurity thresholds (e.g., less than 3% total impurities after 6 months) as required by patents like the '024 patent? This may require a detailed analysis of both parties' stability data for their respective formulations.